Sterling Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sterling Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-91,962	Closed	-$1.52M	–	946
2018 Q2	$1.52M	Sell	91,962 -87	-0.1%	-$1.33K	0.01%	482
2018 Q1	$1.31M	Buy	92,049 +256	+0.3%	+$3.78K	0.01%	527
2017 Q4	$1.34M	Buy	+91,793	New	+$1.29M	0.01%	518
2016 Q1	–	Sell	-21,193	Closed	-$459K	–	1021
2015 Q4	$459K	Buy	21,193 +10,227	+93%	+$199K	﹤0.01%	784
2015 Q3	$217K	Buy	+10,966	New	+$346K	﹤0.01%	909

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Sterling Capital Management's HZNP Position: Q3 2018 in Review

Sterling Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2018, closing a stake of 91,962 shares — an estimated $1.52M sold.

Sterling Capital Management first reported a position in HZNP in Q3 2015 and held it in 5 quarters. The position peaked at $1.52M in Q2 2018. 221 funds tracked by Wall St. Rank hold HZNP as of Q3 2018.

Sterling Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2018 after selling out during the quarter.
Sterling Capital Management sold 91,962 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2018, an estimated $1.52M.
Sterling Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 5 quarters.
Sterling Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.52M in Q2 2018.
221 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2018.

Based on Sterling Capital Management's 13F filing for Q3 2018, filed 1 Nov 2018.